This implies that the anti-oxidative and mitoprotective effects of GLP-1 agonists (Figure 2) forestall the excessive need of repair mechanisms (autophagy and mitophagy) by protecting from oxidative damage in PD or T2DM/insulin resistance-associated hyperglycaemia. The gene discussed is GLP1R; the disease is Parkinson disease.